Search results
Showing 751 to 765 of 2106 results for technology appraisal
Biographies for all current members of the diagnostics advisory committee.
Biographies for all current members of the diagnostics advisory committee.
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
In development Reference number: GID-TA11866 Expected publication date: TBC
Our forward view highlights the areas we will prioritise in the coming year.
In development Reference number: GID-TA11766 Expected publication date: TBC
In development Reference number: GID-TAG509 Expected publication date: 28 September 2016
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
The medical technologies advisory committee makes recommendations on medical devices with the potential to improve patient outcomes, patient experience of treatment and recovery and efficient use of resources.
The medical technologies advisory committee makes recommendations on medical devices with the potential to improve patient outcomes, patient experience of treatment and recovery and efficient use of resources.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
In development Reference number: GID-TA11660 Expected publication date: TBC
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.